Giant cell arteritis: peripheral neuropathy is common.
|
|
|
Clinical bottom line (level 4)
-
A sixth of patients referred with giant cell arteritis for temporal artery biopsy have evidence of peripheral neuropathy.
|
|
Casselli et al:
Neurology
1988;
38:
352-259
|
Expires
February 2001
|
The study
Case series
with
objective
outcomes,
not adjusted
for confounding factors,
not
validated in an independent set of patients.
Setting: university hospital, USA
166 patients
(aged
range 55 to 92 years; median 73,
76%
female)
undergone temporal artery biopsy for suspected giant cell arteritis
Oral steroids (typically prednisone 40-60 mg od) for 13 to 20 months; median 17).
100%
followed for
Mean of 17 months
Outcomes studied:
neuropathy
stroke or transient ischaemic attack
ophthalmic complication
amaurosis fugax
permanent vision loss
large artery disease
carotid arteries
upper limb weakness
lower limb weakness
The evidence
| outcome |
time to outcome |
number of patients/total number |
%
(95% CI) |
| neuropathy
|
Mean of 17 months
|
23/166 |
13.9%
(8.60% to
19.1%) |
| stroke or transient ischaemic attack
|
Mean of 17 months
|
12/166 |
7.23%
(3.29% to
11.2%) |
| ophthalmic complication
|
Mean of 17 months
|
35/166 |
21.1%
(14.9% to
27.3%) |
| amaurosis fugax
|
Mean of 17 months
|
17/166 |
10.2%
(5.63% to
14.9%) |
| permanent vision loss
|
Mean of 17 months
|
14/166 |
8.43%
(4.21% to
12.7%) |
| large artery disease
|
Mean of 17 months
|
52/166 |
31.3%
(24.3% to
38.4%) |
| carotid arteries
|
Mean of 17 months
|
32/166 |
19.3%
(13.3% to
25.3%) |
| upper limb weakness
|
Mean of 17 months
|
30/166 |
18.1%
(12.2% to
23.9%) |
| lower limb weakness
|
Mean of 17 months
|
15/166 |
9.04%
(4.68% to
13.4%) |
Citation
-
Casselli
RJ,
Hunder
GG,
Whisnant
JP:
Neurologic disease in biopsy-proven giant cell (temporal) arteritis.
Neurology
1988;
38:
352-259
Search Terms:
reference in Buchbinder and Detsky: J Rheum 1992: 19: 1220-8
Contributor: Chris Ball and Clare Wotton,
February 2000
Reviewer:
Clinical Question.
| Patient |
patients |
| Intervention or Exposure |
giant cell arteritis |
| Outcome |
prevalence of complications |
|
|